In a groundbreaking development for prostate cancer treatment, the University of California, San Francisco (UCSF) Prostate Center has successfully completed the world's first OnQ Prostate-assisted Focal One Robotic HIFU procedure. This milestone achievement represents a collaboration between Cortechs.ai and EDAP TMS SA, marking a significant advance in precision-guided prostate interventions.
Early Side Effects May Predict Long-term Complications
A significant study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has revealed important findings for prostate cancer patients undergoing radiation therapy. The research indicates that patients who experience side effects early in their radiation treatment course may have an elevated risk of developing more serious long-term urinary and bowel health issues. This insight could prove valuable for treatment planning and patient monitoring.
Genetic Link to Prostate Cancer Risk Identified
Researchers at Vanderbilt University Medical Center have made a crucial discovery regarding prostate cancer risk factors. Their study, published in JCO Precision Oncology, demonstrates that the WNT9B gene, when mutated, increases the risk of developing prostate cancer in adults. This gene, which plays a normal role in embryonic prostate development, provides new insights into the genetic basis of prostate cancer and potential therapeutic targets.
Advances in Melanoma Treatment Research
In parallel developments in cancer research, The Wistar Institute's team, led by Jessie Villanueva, has identified a promising new approach for treating resistant melanoma. Their research, published in Science Translational Medicine, focuses on inhibiting the S6K2 gene, potentially offering new hope for patients with treatment-resistant forms of the disease.
Remembering Dr. Felix Y. Feng
The oncology community mourns the loss of Dr. Felix Y. Feng, who passed away on December 10, 2024, at the age of 48. As the former NRG Oncology Genitourinary Cancer Committee chair and RTOG Foundation member, Dr. Feng made significant contributions to genitourinary cancer research, leading 13 research protocols for NRG and RTOG. His appointment as committee chair in 2018 followed the legacy of his mentor, Dr. Howard Sandler, marking a distinguished career dedicated to advancing cancer treatment.
